Cargando…
The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum
The European Federation for Exploratory Medicines Development (EUFEMED) organized a meeting in Leuven, Belgium entitled ‘The new FIH EMA guideline: Disruptive or constructive?’ to provide a forum for stakeholders to discuss the guideline’s operational impact. The revised EMA Guideline on strategies...
Autores principales: | Breithaupt-Grögler, Kerstin, Hardman, Tim, de Hoon, Jan, Donazzolo, Yves, Rottey, Sylvie, Sourgens, Hildegard, Stringer, Steffan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491518/ https://www.ncbi.nlm.nih.gov/pubmed/31068811 http://dx.doi.org/10.3389/fphar.2019.00398 |
Ejemplares similares
-
EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management
por: Van Bortel, Luc, et al.
Publicado: (2018) -
European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development—Be Prepared
por: Hardman, Tim, et al.
Publicado: (2019) -
How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum
por: Rengelshausen, Jens, et al.
Publicado: (2021) -
Use of integrated clinical trial protocols – A survey in early medicines development
por: Erb-Zohar, Katharina, et al.
Publicado: (2018) -
Unintended drug exposure during pregnancy in clinical trials – a survey in early drug development
por: Erb-Zohar, Katharina, et al.
Publicado: (2021)